Study Summary
This study is a single-arm, open-label, dose-escalating trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of anti human CI-135 (FLT3) CAR-T Injection , and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory Acute Myeloid Leukemia.
Want to learn more about this trial?
Request More InfoInterventions
Human Derived anti-CI135 CAR-T InjectionDRUG
Autologous genetically modified anti-CI135 CAR transduced T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| First Affiliated Hospital of Soochow University | Suzhou | Jiangsu | China |